17, January 27, 1981, part 50). The pretreatment/ screening visit will determine patient eligibility according to the inclusion and exclusion criteria. All subjects must undergo a number of b aseline evaluations as part of this screening visit, as detailed below. All of thes e evaluations should be conducted within 21 ± 4 days of starting the protocol . This information is also summarized in the Study Calendar (Tabl es 1A and 1B ). • informed consent (including research authorization ) • demographic information • medical history, including review of systems • performance status, using ECOG or Karnofsky scales (Append ix A) • physical examination • vital signs: temperature, pulse, sitting blood pressure, respiratory rate • height and weight • current medication list, including drug allergies/adverse events • hematological laboratories (hemoglobin, hematocrit, white blood cell count with differential [including a bsolute eosinophil count], platelets); coagulation profile (INR, aPTT) if clinically indicated • serum chemistry profile (sodium, potassium, chloride, bicarbonate, urea, creatinine, glucose, calcium, albumin, total protein, bilirubin, ALT, AST, alkaline phos phatase) • serum PSA level • sera for immunoassays (Pre -treatment) (see Section 5.4) • CT (If allergic to CT scan contrast, obtain MRI with contrast) and/ or bone scan , only if clinically indicated (not mandatory) • central pathologic review of prostate core biopsies After all r elevant screening informatio n is documented, r egistration should be finalized and appropriate documents ( i.e., signed informed consent, supporting source documentation for eligibility ) should be faxed or emailed to the pr ogram manager . Information on patients who do not meet eligibility criteria to participate in this study ( i.e., screening failures) should also be captured at the pretreatment visit. 5.3 Radical Prostatectomy The following must be performed on the day of radical prostatectomy, which i tself should occur 28 (±3) da ys after the administration of degarelix acetate . • medical history • performance status • physical examination , including vital signs Androgen suppression with prostate GVAX and cyclophosphamide J1265 Johns Hopkins University 27 of 68 J1265 PROT (Vers) 1.4 113012 • review of medicatio n list • review of toxicity/adverse events • hematological laboratories and serum c hemistry profil e • serum PSA • sera for immunoassays (see Section 5.4) • collection of prostatectomy tissue for analysis of study endp oints • pathological processing of prostatectomy specimen according to standard procedures 5.4 Sera for Immunoassays At each time point (Pre -treatment , at prostatectomy , and at follow -up visit ), the followi ng research blood samples should be collected and processed as outlined below : • Draw approximately 10 mL of peripheral blood into 2 plain (red top) or SST (gold top) tu bes, each con taining ≥5 mL of blood per vacutainer. • Allow blood to coagulate for 20 minutes, then centrifuge at 25oC, 1500 x g (2700-3000 rpm) , for 15 minutes.